阿那白滞素生物类似药(Hamad Medical Corp.)(Anakinra biosimilar(Hamad Medical Corp.))

概要

基本信息

药物类型

白细胞介素、生物类似药

别名-

靶点

IL1R1

作用方式

拮抗剂

作用机制

IL1R1拮抗剂(白细胞介素-1受体拮抗剂)

治疗领域

感染呼吸系统疾病其他疾病

在研适应症-

非在研适应症

新型冠状病毒感染细胞因子释放综合征

原研机构

Hamad Medical Corp.

在研机构-

非在研机构

Hamad Medical Corp.

权益机构-

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 27164

当前序列信息引自: *****

关联

5

项与阿那白滞素生物类似药(Hamad Medical Corp.) 相关的临床试验

NCT04643678

/ Completed临床2/3期

Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial

Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes.
Anakinra - an interleukin (IL)-1 receptor antagonist - had showed survival benefits in patients with macrophage activation syndrome (MAS) and sepsis and was investigated for the use in COVID-19 infection with promising outcomes.

开始日期2020-10-30

申办/合作机构

Hamad Medical Corp.

EUCTR2020-001754-21-FR

/ Not yet recruiting临床3期IIT

An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease - INFLAMMACOV

开始日期2020-05-19

申办/合作机构

Assistance Publique Hôpitaux de Marseille

EUCTR2018-005046-10-NL

/ Not yet recruiting临床2期IIT

Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan – A randomized controlled trial - AFFECT-2

开始日期2019-07-23

申办/合作机构